Estrogen treatment suppresses forebrain p75 neurotrophin receptor expression in aged, noncycling female rats.
There is increasing evidence that estrogen has beneficial effects on cognition, both in humans and in rodents, and may delay Alzheimer's disease onset in postmenopausal women. Several rodent studies have utilised the ovariectomy model to show estrogen regulation of the p75 neurotrophin receptor, TrkA, and markers of acetylcholine synthesis in the cholinergic basal forebrain. We studied estrogenic effects in aged (16-17-month-old), noncycling rats. Estrogen treatment for 10 days drastically reduced p75(NTR) immunoreactivity in the rostral parts of the basal forebrain. The number of p75(NTR)-immunoreactive neurons was decreased, and those neurons remaining positive for p75(NTR) showed reduced p75(NTR) staining intensity. In vehicle-treated rats, almost all choline acetyltransferase-immunoreactive neurons were p75(NTR) positive (and vice versa), but, in estrogen treated rats, large numbers of choline acetyltransferase-immunoreactive cells were negative for p75(NTR). Similar levels of p75(NTR) down-regulation in the rostral basal forebrain were found when estrogen treatment was extended to 6 weeks. There was no reduction in the number of p75(NTR)-immunoreactive neurons in the caudal basal forebrain after 10 days of treatment. After 6 weeks of treatment, however, there was evidence of p75(NTR) down-regulation in the caudal basal forebrain. There was no evidence of hypertrophy or atrophy of cholinergic neurons even after 6 weeks of estrogen treatment. Considering the evidence for the role of p75(NTR) in regulating survival, growth and nerve growth factor responsiveness of cholinergic basal forebrain neurons, the results indicate an important aspect of estrogen's effects on the nervous system.
Ping
Sophie E
SE
Department of Physiology, University of Melbourne, Parkville, Australia.
Greferath
Ursula
U
Barrett
Graham L
GL
D000375:Aging / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D000780:Anestrus / Q000097:blood / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D002795:Choline O-Acetyltransferase / Q000096:biosynthesis; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology*; D004958:Estradiol / Q000097:blood / Q000494:pharmacology; D004967:Estrogens / Q000097:blood / Q000494:pharmacology*; D005260:Female; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D016548:Prosencephalon / Q000187:drug effects* / Q000378:metabolism*; D051381:Rats; D020800:Receptor, Nerve Growth Factor; D017475:Receptors, Nerve Growth Factor / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*
D004967:Estrogens; D020800:Receptor, Nerve Growth Factor; D017475:Receptors, Nerve Growth Factor; D004958:Estradiol; D002795:Choline O-Acetyltransferase